Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06048224 |
Recruitment Status :
Completed
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
|
Sponsor:
Zhejiang Hisun Pharmaceutical Co. Ltd.
Information provided by (Responsible Party):
Zhejiang Hisun Pharmaceutical Co. Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | September 14, 2021 |
Actual Study Completion Date : | January 31, 2022 |